Brief: Recognify Life Sciences Says Schizophrenia Drug Fails To Meet Main Goal In Trial

AtaiBeckley

25/07/2025 21:12

July 25 (Reuters) - Recognify Life Sciences:

INIDASCAMINE SHOWS NUMERICAL IMPROVEMENT BUT LACKS SIGNIFICANCE

PROVIDES UPDATE ON PHASE 2B TRIAL OF INIDASCAMINE IN PATIENTS WITH COGNITIVE IMPAIRMENT ASSOCIATED WITH SCHIZOPHRENIA

INIDASCAMINE EXHIBITS FAVORABLE SAFETY AND TOLERABILITY PROFILE

PHASE 2B CLINICAL TRIAL EVALUATING INIDASCAMINE DID NOT MEET ITS PRIMARY ENDPOINT

Source text: [ID:]

Further company coverage: 9VC.DE

 ((Reuters.Briefs@thomsonreuters.com;))